Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber’s Congenital Amaurosis Type 10
Results of the first phase 3 trial in this field were announced.
Ophthalmic Product Development Insights
Early detection may allow treatment, and possibly reversal. Part 2 of a two-part series.
When it comes to your site’s qualifications, you must be forthcoming with study sponsors.
A look at the latest research from multiple corners of ophthalmology, from gene therapy to dry eye.
Numerous approaches to treatment of dry AMD are under development.
Explaining both the demands and potential rewards of a clinical trial can make patients more
likely to participate fully in the protocol.